Table 2.

Use of cardiac biomarkers (upper panel) and global longitudinal strain (lower panel) in the routine monitoring of cancer patients receiving anthracyclines by center type.

	General hospital	Cancer center
Troponin T or I (n/%)	7/87 (8%)	0/9 (0%)
BNP or NT-pro-BNP (n/%)	2/87 (2%)	0/9 (0%)
Troponin plus BNP or NT-pro-BNP (n/%)	19/87 (22%)	2/9 (22%)
Global longitudinal strain*	37/87 (43%)	4/9 (44%)

BNP, B-type natriuretic peptide;

^*Taking together the answers “always” and “depending on the operator” (see text for details).